30 August 12 11:21–(NYSE: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) approval tbo-filgrastim, a biological drug for the treatment of severe neutropenia (a reduction in white blood cells. in patients receiving chemotherapy for certain types of cancer. Tbo-filgrastim is a biosimilar (or copy) of Amgen Inc.’s (Nasdaq: AMGN) biologic drug Neupogen.

Tbo-filgrastim is a short-acting recombinant form of granulocyte colony-stimulating factor (G-CSF) to stimulate the bone marrow to produce white bloods cells to reduce the duration of severe neutropenia, which can make patients more susceptible to potentially life-threatening bacterial infections…Read More>>

Share/Bookmark